IMMUNOCORE HLDGS ADS/1 - Asset Resilience Ratio
IMMUNOCORE HLDGS ADS/1 (6YG) has an Asset Resilience Ratio of 37.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of IMMUNOCORE HLDGS ADS/1 to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how IMMUNOCORE HLDGS ADS/1's Asset Resilience Ratio has changed over time. See 6YG net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down IMMUNOCORE HLDGS ADS/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMMUNOCORE HLDGS ADS/1 (6YG) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €396.44 Million | 37.15% |
| Total Liquid Assets | €396.44 Million | 37.15% |
Asset Resilience Insights
- Very High Liquidity: IMMUNOCORE HLDGS ADS/1 maintains exceptional liquid asset reserves at 37.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
IMMUNOCORE HLDGS ADS/1 Industry Peers by Asset Resilience Ratio
Compare IMMUNOCORE HLDGS ADS/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for IMMUNOCORE HLDGS ADS/1 (2023–2025)
The table below shows the annual Asset Resilience Ratio data for IMMUNOCORE HLDGS ADS/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.15% | €396.44 Million ≈ $463.48 Million |
€1.07 Billion ≈ $1.25 Billion |
+1.02pp |
| 2024-12-31 | 36.12% | €364.64 Million ≈ $426.31 Million |
€1.01 Billion ≈ $1.18 Billion |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€597.00 Million ≈ $697.96 Million |
-- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more